Literature DB >> 7619818

Mechanism of protein synthesis inhibition by didemnin B in vitro.

B V SirDeshpande1, P L Toogood.   

Abstract

The cytotoxic and immunosuppressive marine depsipeptide didemnin B is a potent inhibitor of protein biosynthesis in intact cells. Here, didemnin B is shown to inhibit protein synthesis in vitro during the elongation cycle, by preventing eukaryotic elongation factor 2-(eEF-2-) dependent translocation. No inhibition of aminoacyl-tRNA delivery or of peptidyltransferase activity is observed. Didemnin B stimulates eEF-1 alpha-dependent aminoacyl-tRNA binding to rabbit reticulocyte ribosomes, and eEF-1 alpha is required for inhibition of the subsequent translocation of phenylalanyl-tRNA(Phe) from the A- to the P-site. These observations suggest that didemnin B prevents translocation by stabilizing aminoacyl-tRNA bound to the ribosomal A-site, similar to the antibiotic kirromycin, and consistent with the known affinity of didemnins for elongation factor eEF-1 alpha [Crews et al. (1994) J. Biol. Chem. 269, 15411]. Unlike kirromycin, didemnin B does not prevent peptide bond formation, so inhibition is observed only at the translocation step. Inhibition of translocation by didemnin B is attenuated by increasing concentrations of eEF-2.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7619818     DOI: 10.1021/bi00028a030

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  17 in total

1.  Inhibitors of protein synthesis identified by a high throughput multiplexed translation screen.

Authors:  Olivia Novac; Anne-Sophie Guenier; Jerry Pelletier
Journal:  Nucleic Acids Res       Date:  2004-02-09       Impact factor: 16.971

2.  Eukaryotic protein synthesis inhibitors identified by comparison of cytotoxicity profiles.

Authors:  Jenny Chan; Shakila N Khan; Isabelle Harvey; William Merrick; Jerry Pelletier
Journal:  RNA       Date:  2004-03       Impact factor: 4.942

3.  Total synthesis of Lys(3) tamandarin M: a potential affinity ligand.

Authors:  Kenneth M Lassen; Madeleine M Joullié
Journal:  Org Lett       Date:  2010-10-29       Impact factor: 6.005

Review 4.  Drug development from marine natural products.

Authors:  Tadeusz F Molinski; Doralyn S Dalisay; Sarah L Lievens; Jonel P Saludes
Journal:  Nat Rev Drug Discov       Date:  2008-12-19       Impact factor: 84.694

Review 5.  Nonproteinogenic amino acid building blocks for nonribosomal peptide and hybrid polyketide scaffolds.

Authors:  Christopher T Walsh; Robert V O'Brien; Chaitan Khosla
Journal:  Angew Chem Int Ed Engl       Date:  2013-05-31       Impact factor: 15.336

Review 6.  Enriching cancer pharmacology with drugs of marine origin.

Authors:  Paula C Jimenez; Diego V Wilke; Paola C Branco; Anelize Bauermeister; Paula Rezende-Teixeira; Susana P Gaudêncio; Leticia V Costa-Lotufo
Journal:  Br J Pharmacol       Date:  2019-12-23       Impact factor: 8.739

7.  Inhibition of translation by cytotrienin A--a member of the ansamycin family.

Authors:  Lisa Lindqvist; Francis Robert; William Merrick; Hideaki Kakeya; Christopher Fraser; Hiroyuki Osada; Jerry Pelletier
Journal:  RNA       Date:  2010-10-13       Impact factor: 4.942

8.  Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin.

Authors:  Tilman Schneider-Poetsch; Jianhua Ju; Daniel E Eyler; Yongjun Dang; Shridhar Bhat; William C Merrick; Rachel Green; Ben Shen; Jun O Liu
Journal:  Nat Chem Biol       Date:  2010-01-31       Impact factor: 15.040

9.  Chlorolissoclimides: new inhibitors of eukaryotic protein synthesis.

Authors:  Francis Robert; Hong Qing Gao; Marwa Donia; William C Merrick; Mark T Hamann; Jerry Pelletier
Journal:  RNA       Date:  2006-03-15       Impact factor: 4.942

10.  Bouvardin is a Radiation Modulator with a Novel Mechanism of Action.

Authors:  Stefanie A Stickel; Nathan P Gomes; Barbara Frederick; David Raben; Tin Tin Su
Journal:  Radiat Res       Date:  2015-09-28       Impact factor: 2.841

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.